Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025




Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.

“These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has multiple opportunities to engage with and understand these important results,” said Ben Zeskind, Ph.D., CEO of Immuneering.

Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 9502940. A webcast replay will be available from the “Investors” section of the Company’s website here. The Immuneering September 2025 corporate presentation can be found here and the September 24, 2025 press release announcing updated overall survival and safety data in first-line pancreatic cancer patients can be found here.

About Immuneering
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com. 

Media Contact:
Carson Creehan
817-412-1096
carson.creehan@padillaco.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com

Glucose Health, Inc. Announces Officer Changes Effective September 30, 2025




Glucose Health, Inc. Announces Officer Changes Effective September 30, 2025

BENTONVILLE, Ark., Sept. 26, 2025 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTC: GLUC) today announced that its Chief Executive Officer and Chief Financial Officer has resigned, effective September 30, 2025, for personal reasons. The resignation was not requested by the Company.

Murray Fleming, the Company’s sole Director, will perform the functions of Chief Executive Officer and Chief Financial Officer in his capacity as Director to provide administrative continuity and will assist shareholders in identifying new officers. This service will continue until one of the following occurs:

• Permanent successors, if any, are appointed.
• The Company determines to wind down and cease operations.
• The Board takes further action with respect to officer appointments.

There were no disagreements with the Company on any matter relating to its operations, policies, or practices.

The Company confirms that day-to-day operations will continue under the Director’s oversight; however, the Company has limited operating capital and uncertain prospects to continue as a going concern.

For further information, please contact:
info@glucosehealthinc.com 

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI




Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has closed the initial tranche of its previously announced $150 million Bitcoin (BTC) investment in Datavault AI Inc. (Nasdaq: DVLT, “Datavault”), pursuant to which Scilex is expected to receive up to an aggregate of 278,914,094 shares of Datavault common stock (at an effective purchase price of $0.5378 per share) (subject to adjustment for stock splits and similar transactions). At the closing of this initial tranche, Scilex received 15,000,000 shares of Datavault common stock with the remainder to be issued in a second tranche in the form of a pre-funded warrant to purchase Datavault common stock, subject to approval by Datavault’s stockholders of, among other things, the issuance of Datavault shares to Scilex in excess of 19.99% of Datavault’s total pre-financing shares outstanding.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.

The company is headquartered in Beaverton, OR.

Learn more about Datavault AI at www.dvlt.ai

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, potential Datavault stockholder approval and timing for closing of the second tranche of Scilex’s investment in Datavault,   future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to achieve the benefits of the transactions contemplated with Datavault, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Datavault; the risk that the transactions contemplated with Datavault disrupts current plans and operations; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

Shape Therapeutics Announces Multiple Oral and Poster Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress




Shape Therapeutics Announces Multiple Oral and Poster Presentations at the European Society of Gene & Cell Therapy 32nd Annual Congress

Talks will cover the use of a novel BBB-penetrant, AAV5-derived CNS capsid and development of an RNA-targeting disease-modifying gene therapy, SHP-201, for treatment of Parkinson’s Disease

SEATTLE, Sept. 26, 2025 (GLOBE NEWSWIRE) — Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of two oral presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) 32^nd congress that will take place October 7-10, 2025 in Seville, Spain.

Details of the presentations are below:

Presentation Title: Engineered AAV5 capsid SHP-DB1 efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson’s disease-critical substantia nigra
Presenter: Dr. Adrian Briggs, Shape Therapeutics
Session Date and Time: Tuesday, October 7, 2025, 17:00-19:30 CT
Session Title: Session 2B
Session Room: Room Parallel B

Presentation Title: Targeted Knockdown of Alpha Synuclein in the Brain Supports the Therapeutic Development of SHP-201 for Parkinson’s Disease
Presenter: Dr. Leah Helton, Shape Therapeutics
Session Date and Time: Friday, October 10, 2025, 11:00-13:00 CT
Session Title: Session 12c: Gene Editing III: Technology & applications
Session Room: Room Parallel C

About Shape Therapeutics

Shape Therapeutics is leveraging AI to develop new payload, delivery and manufacturing technologies for the gene therapy industry. Alongside the company’s own RNA-targeting gene therapy portfolio, Shape’s platform includes AAV capsids with enhanced tropism and penetration profiles, enabling delivery of genetic medicines to previously inaccessible tissues. The company is headquartered in Seattle, Washington. You can find us at shapetx.com and on LinkedIn.

Media Contact:
info@shapetx.com

New Clue Survey Reveals Misinformation About Reproductive Health is a Top Concern for American Women




New Clue Survey Reveals Misinformation About Reproductive Health is a Top Concern for American Women

• 82% of U.S. women are concerned about encountering medical misinformation online
• 55% of U.S. women have encountered medical information online that they do not trust
• Misinformation is leaving American women feeling confused (40%) and anxious (37%)
• Clue appoints Dr. Charis Chambers MD (AKA The Period Doctor) as Chief Medical Officer as part of the brand’s continued commitment to help women better understand their bodies through science-based, medically credible information

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) — New data released today reveals medical misinformation about reproductive health is a major concern for 82% of U.S. women* with more than 1 in 2 saying they have seen reproductive health information online that they did not trust.

The survey, conducted by Clue, the #1 women-led period and cycle tracker trusted by over 100 million worldwide, paints a clear picture of the impact medical misinformation has on American women.

When it comes to menstrual cycles, 28% don’t know when they are most fertile and over half (58%) are unable to correctly name all four stages of the menstrual cycle – menstruation, ovulation, follicular phase and luteal phase. Around 1 in 6 (17%) women are unable to identify whether their cycles are irregular or not.

1 in 5 (20%) women believe you can’t get pregnant during your period – a common fertility myth – while almost 1 in 10 (9%) believe infertility is primarily a female problem. 36% say they mistrust the information they are exposed to about hormonal contraception and a further 47% claim this has made them less likely to use it. 62% of women say they wish they had learned more about fertility earlier.

As the data shows a growing need for science-based reproductive education, Clue today announces the appointment of Dr. Charis Chambers MD, a board-certified OB-GYN and widely respected health educator, as its new Chief Medical Officer. Known for her evidence-based and approachable voice on social media as “The Period Doctor,” Dr. Chambers brings deep clinical expertise and a passion for health equity to Clue’s mission.

“Too many women and people with cycles are left in the dark about what’s happening in their own bodies,” said Dr. Chambers. “They’re misinformed, dismissed, or confused, especially when it comes to conditions like PCOS or major transitions like menopause. I believe everyone deserves access to clear, credible, personalized care, which is why I’m proud to partner with Clue – a brand built on a foundation of science, credibility, and trust.”

Clue’s survey also found that many women struggle to find accurate and truthful information about reproductive health. More than half (58%) of respondents aged 16-24 reported relying on unverified sources like social media to understand their reproductive health, while an additional 40% say they’ve followed at least one unqualified “healthfluencer” for advice on periods, hormones, or fertility. The findings cement a clear need for better education, access, and tools that center around science and data.

These knowledge gaps have real-world consequences. Over 40% of women report feeling confused or anxious (37%) after encountering conflicting health information online. The impact isn’t just mental either.

For women living with polycystic ovary syndrome (PCOS) – a condition that affects 1 in 10 and is a leading cause of infertility – misunderstandings about the menstrual cycle can mean years of delayed diagnosis and treatment. Clue’s survey highlights how common this problem is, as 34% of women reported having a reproductive health concern dismissed as “normal” by a provider, only to later discover it was anything but.

This new picture of the lack of knowledge, information and accurate insight reinforces the critical role of science-based, research-led companies in the space to provide scientifically credible, and medically sound guidance, to women today.

“This consumer data highlights both the complexity and the opportunity in advancing reproductive health education,” said Louise Troen, Chief Marketing Officer at Clue. “Our commitment to connecting the dots between personal feelings, intelligent symptom tracking and science-based insights, has never been more important and we are proud to offer a product which – through rich data and world class academic research – empowers millions of women to better understand their bodies and make confident, informed choices. Dr. Chambers brings a wealth of expertise and a powerful voice to our mission, and her appointment reflects our ongoing commitment to expanding access to trusted, inclusive health information.’’

Digital tools such as Clue play a vital role in helping to close the knowledge gap and empowering women to better understand their health. Clue’s own data strongly demonstrates the value of accessible, science-based information as 90% of users say using the app has helped them gain a better understanding of their body and cycle patterns¹.

With the appointment of Dr. Chambers alongside Clue’s existing team of in-house scientists, the brand is continuing to empower women and people with cycles to take control of their reproductive health at every stage of life.

To mark the partnership, Dr. Chambers will be tackling some of the most common period and cycle myths in a no-nonsense video across her Instagram page. To learn more about Clue and access evidence-based women’s health education, visit helloclue.com.

About the Consumer Survey

*The research was conducted by Censuswide, among a sample of 2,000 consumers in the US who menstruate (aged 16+). The data was collected between 04.09.2025 – 08.09.2025. Censuswide abides by and employs members of the Market Research Society and follows the MRS code of conduct and ESOMAR principles. Censuswide is also a member of the British Polling Council.

About Clue

Clue is the #1 women-led period and cycle tracker, loved by over 100 million women and people with cycles around the world.

Beyond period tracking, Clue helps you turn your cycle into a powerful tool to help navigate your health journey by making sense of your hormones and discovering your unique patterns.

Whether you want to simply understand your cycle, try to conceive, track your pregnancy, or navigate perimenopause, Clue is your intelligent science-backed, data-driven, health guide.

Join the movement that’s changing the future of female health, one data point at a time. Try Clue free, today.

Footnotes:
1. Based on a global cross-sectional survey of 11,910 users of the Clue menstrual cycle tracking app, ages 18 to 58, to assess menstrual health experiences, healthcare interactions, and app use conducted by Clue

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de3f075c-4f00-4227-97e8-f85406f4d593

CONTACT: press@helloclue.com

UPDATE — ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic




UPDATE — ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) — ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04^®, the company’s phase 2 Alzheimer’s candidate.

“This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering from this devastating condition.”

The SBIR program is one of the most competitive NIH funding initiatives, designed to support small businesses advancing cutting-edge science with high commercial potential.

“The NIH’s support underscores the strength of our science and alongside our UK ILAP designation (conditional market approval after phase 2) and EU CTAs validates AD04^® as a global program. This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access,” said Jeffrey Madden, Co-Founder and CEO.

This news follows the recent publication of encouraging AD04^® results in The Journal of Prevention of Alzheimer’s Disease (JPAD) https://pubmed.ncbi.nlm.nih.gov/40953123/. The publication highlighted encouraging results from AD04’s earlier Phase 2 trial. A follow-up independent statistical analysis confirmed that the positive effects seen in patients were reliable and not due to chance. These findings suggest that AD04 produced a treatment effect that compared favorably to monoclonal Alzheimer’s therapies already on the market, while being easier to take, safer, and more affordable.

About AD04™

ADvantage Therapeutics is developing AD04™ as a new class of therapeutic for mild Alzheimer’s disease that exhibits durable multifaceted effects, including both immediate symptomatic relief and long-term disease-modification. The compound has been used extensively as an adjuvant in human and animal vaccination programs. In a previous trial, AD04™ serving as a control against another compound appeared to demonstrate statistically significant slower decline in cognitive and quality of life clinical measures compared to other treatment groups. AD04™ also showed slower decline in hippocampal volume as a biomarker.

The Company believes that rather than being limited to a specific aspect of AD pathology, such as amyloid beta or tau, AD04™ may restore expression of genes in lipid metabolism, improve phagocytosis and reduce inflammation. Through multiple mechanisms AD04™ functions as an immunomodulator, stimulating and/or regulating the immune system to reduce AD pathology.

About Alzheimer’s Disease

About fifty million people worldwide suffer from AD, which is the sixth leading cause of death in industrialized countries. In 2019, the World Health Organization estimated the total worldwide cost of dementia at $1.3 trillion and expects this cost to rise to $2 trillion by 2030. The socio-economic burden of AD is enormous. AD devastates the lives of patients and their families. AD victims lose their memory and independence. AD is a high unmet medical need as there are currently no disease-modifying drugs approved worldwide. The availability of a safe, effective, affordable drug would transform the life of an AD patient from accepting a debilitating disease to the retention of personality, independence, and dignity.

About ADvantage Therapeutics, Inc.

Headquartered in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on AD. The Company’s lead compound AD04™ is a subcutaneous injectable therapy that is ready to enter, confirmatory Phase 2b clinical trials in Europe, to evaluate its safety and efficacy in early AD patients. The Company believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to attack the misfolded proteins, beta amyloid and tau. The Company is exploring additional approaches to mitigating neurodegenerative disease, among them increasing the levels of Klotho, a life and health extending protein which will have an overall impact on longevity.

Funding Acknowledgment

Research reported in this press release is supported by the National Institute on Aging (NIA) of the National Institutes of Health under Award Number 1R44AG091827-01. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.

For more information, please visit: www.advantagetherapeutics.com

Media Contact:
Jeffrey Madden
Chief Executive Officer
195 NW 40th Street
Miami, FL 33127
Jeff@advantagetherapeutics.com

Shriners Hospitals for Children Canada Hosts Fundraising Gala Celebrating 100 Years of Hope, Healing, and Innovation




Shriners Hospitals for Children Canada Hosts Fundraising Gala Celebrating 100 Years of Hope, Healing, and Innovation

MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) — Shriners Hospitals for Children Canada is proud to celebrate its centennial with an extraordinary black-tie evening of celebration, reflection, and inspiration. Members of the media are cordially invited to join over 400 at the Gala of the Century, commemorating 100 years of hope, healing, and innovation.

Date: Saturday, October 4, 2025

Location: Salon Richmond, 550 Richmond Avenue, Montreal, QC. H3J 1V3

Time: 6:00 p.m.

RSVP information: Attendance must be confirmed by no later than October 1, 2025, to moncommunications@shrinenet.org.

The Gala will feature moving patient stories, captivating artistic performances, commemorative videos, gourmet dining, and inspiring encounters with current and former patients— all in celebration of a century of care and innovation.

Backgrounder on the hospital’s history: https://www.shrinerschildrens.org/en/news-and-media/news/2025/02/shriners-hospitals-for-children-canada-centennial-celebration

About Shriners Hospitals for Children Canada

Established in Montreal in 1925, Shriners Hospitals for Children Canada is a bilingual, short-term, acute care hospital, providing ultra-specialized orthopaedic care to children from across Canada and around the world. The mission of the hospital is to provide treatment and rehabilitation to infants, children and young adults with orthopaedic and neuromuscular problems such as scoliosis, osteogenesis imperfecta (brittle bone disease), clubfeet, hip dysplasia, leg length discrepancies and cerebral palsy, among others. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital provides clinical experience and teaching for residents and allied professionals within its outstanding facility on the Glen site. The hospital is present in communities across Canada, thanks to telemedicine, outreach clinics and satellite clinics.

Information
Timothy Fisher
Director of Marketing and Communications
Timothy.Fisher@shrinernet.org

SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer




SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer

FORT LAUDERDALE, Fla., Sept. 26, 2025 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Naveen Kumar Amar as the Company’s Chief Financial Officer, effective September 24, 2025. Mr. Amar is assuming the Chief Financial Officer role, on a permanent basis, from Dr. Vishwa Srivastava, who has served as the Company’s Interim Chief Financial Officer since July 2025. Dr. Vishwa Srivastava will continue in his capacity as the Company’s Chief Executive Officer – Asia Pacific.

Mr. Amar brings to SS Innovations more than 25 years of global finance leadership experience spanning a wide range of industries and geographies. During his career, he has amassed expertise in financial accounting and reporting, planning and analysis, budgeting, forecasting, corporate finance, treasury operations, governance, internal controls, and both U.S. and Indian GAAP, among other areas. He has been recognized as one of India’s top financial executives by various publications and organizations, including Forbes India magazine, Forbes Asia magazine, CFO India Forum, and Chartered Institute of Management Accountants, London.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Amar brings to SS Innovations a strong track record of building best-in-class finance operations, effective cross-functional teams, and successful businesses across diverse industries and geographies. We are thrilled to welcome a seasoned financial executive of his caliber to our leadership team as we expand the global presence of our advanced, cost-efficient SSi Mantra surgical robotic system.”

Mr. Amar added, “I am honored to be joining SS Innovations at this exciting stage in its journey to democratize access to advanced surgical robotic care and I look forward to helping the team drive growth and deliver sustainable long-term shareholder value.”

Most recently, Mr. Amar has provided virtual CFO services to clients based in the United States, Canada and the United Kingdom. Among his previous positions, Mr. Amar served as Head of Finance & Commercial for SpiceXpress, the cargo division of SpiceJet; Global CFO for Munch Ado India Private Ltd., a software enterprise technology provider; Senior Vice President – Finance & Compliance and Company Secretary for MSD Wellcome Trust Hilleman Laboratories Private Ltd., a global vaccine manufacturer; Chief Financial Officer – India & Australia and Company Secretary for EDirect Proprietary Ltd., a telecommunications provider; and India Manager – Financial Consolidation and Company Secretary for GE India.

Mr. Amar graduated with a Bachelor of Commerce degree from the University of Delhi and received a post graduate diploma in Business Management from All India Management Association’s Centre of Management Education. In addition, he earned the Chartered Accountant designation from the Institute of Chartered Accountants of India as well as the Company Secretary designation from the Institute of Company Secretaries of India.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide




Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide

Now Operating in 19 States Nationwide

Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) —

Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide

Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company’s decade-long track record of helping patients access medical cannabis care through secure and compliant telehealth.

Since launching in 2015, PrestoDoctor has provided care to over 500,000 patients nationwide, building one of the most established and trusted platforms for medical cannabis telehealth services. Over ten years of continuous operation, the platform has developed a reputation for compliance, convenience, and patient satisfaction, connecting individuals with licensed clinicians in their home states.

PrestoDoctor’s Connecticut launch aligns with state rules that permit telemedicine for medical marijuana certifications and require certifications to be issued by Connecticut-licensed physicians, PAs, or APRNs. The platform will connect patients with in-state clinicians and provide step-by-step guidance to complete the Department of Consumer Protection’s medical marijuana registration process.

“Our goal is to make compliant access to care faster and more convenient for qualified Connecticut patients,” said David Tobias, CEO of Dogecoin Cash. “For a decade, PrestoDoctor has proven its ability to deliver secure, patient-centered care through telehealth. With more than 500,000 patients served and 19 states now live, we are proud to expand into Connecticut and continue building on our leadership position in this space.”

• Fully online appointments with Connecticut-licensed clinicians for qualifying conditions recognized by the state medical program.
• Step-by-step guidance on state registration after a clinician issues a certification.
• Privacy and security consistent with PrestoDoctor’s established telehealth workflows in other states.
• Flexible payments, including traditional payment methods as well as select cryptocurrencies such as Dogecoin (DOGE), Bitcoin (BTC), Ethereum (ETH), USD Coin (USDC), and Tether (USDT).

About PrestoDoctor

Founded in 2015, PrestoDoctor has been operating for 10 years and has served over 500,000 patients across the United States. With its expansion into Connecticut, PrestoDoctor now operates in 19 states nationwide, providing an online experience focused on speed, privacy, and compliance. PrestoDoctor also offers patients the ability to pay for services using traditional methods or select cryptocurrencies, reflecting the Company’s commitment to accessible, modern, and forward-looking healthcare solutions.

About Dogecoin Cash, Inc. (OTCQB: DOGP)

Dogecoin Cash, Inc. (OTCQB: DOGP) is a publicly traded company with operations that include telehealth services through its subsidiary PrestoDoctor. For more information and Company disclosures, visit OTC Markets.

Investor & Media Contact
Dogecoin Cash, Inc.
Info@dogecoincashinc.com

Notices & Safe Harbor

Regulatory Notice (Connecticut): Medical marijuana certifications in Connecticut may be issued only by Connecticut-licensed physicians, physician assistants, or APRNs to qualifying patients who meet state criteria. Patients must complete state registration with the Connecticut Department of Consumer Protection after receiving a certification from a clinician. Telemedicine is permitted for certifications pursuant to Public Act 23-97.

No Offer or Solicitation: This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Forward-Looking Statements: This release contains “forward-looking statements” within the meaning of federal securities laws, including statements regarding the timing, availability, scope, and expected benefits of PrestoDoctor’s services in Connecticut and other markets. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including changes in laws or regulations, operational or licensing requirements, payer and patient adoption, competitive dynamics, and other factors described in the Company’s disclosures on OTC Markets. The Company undertakes no obligation to update forward-looking statements except as required by law.

CONTACT: info@dogecoincashinc.com

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented




BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented

September 26, 2025
News Release

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented

COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acute Kidney Injury (AKI) and management of the patient’s journey and clinical decision making.

International Pediatric Transplant Association (IPTA) meets every 2 years for surgeons, nephrologists, hepatologists, and critical care clinicians. Berlin hosted an event with over 500 participants with tracks for liver, heart and kidney transplant topics. AKI is a topic of concern for these patients and was addressed in multiple sessions. Dr. Kyle Merrill of Iowa, USA, and Dr. June Oh of Hamburg, Germany, presented a special session sponsored by BioPorto noting their use of NGAL in patient cases to over 100 attendees. Dr. Merrill also shared a poster entitled “Utility of NGAL in Resolution of Delayed Graft Function after Kidney Transplantation: Case Report.”

The 5th International Symposium on AKI in Children begins today, September 26, in Cincinnati, OH, USA, and is hosted by Dr. Stuart Goldstein of Cincinnati Children’s Hospital Medical Center (CCHMC) and Dr. Akash Deep of Kings College Hospital, London. The conference goals include scientific review and collaboration across pediatric patients and communities worldwide and is supported by The Heart Center at CCHMC. Other collaboration communities include Research Incubator in Neonatal Kidney Disease (RINK) which includes AKI and biomarkers in their work.

NGAL research will be noted in multiple abstracts and posters by academic clinicians from across the US and other countries. One publication of particular interest is “Urine neutrophil gelatinase-associated lipocalin predicts kidney support therapy duration and liberation in critically ill children” which discusses the use of NGAL for initiation and liberation from Continuous Renal Replacement Therapy (CRRT), a form of dialysis. As there is no current standard of care or clinical practice in these areas, the work with the NGAL biomarker is an important start to this area of research and possible future indications for diagnostic testing.

For those attending the symposium on AKI in children, please visit the BioPorto booth.

BioPorto is proud to sponsor these congresses and their attendees.

To subscribe to news from BioPorto, please sign up at https://bioporto.com/investor-contact/.
For product information, please sign up at https://bioporto.com/schedule-a-meeting/.

For further information
Jennifer Zonderman, BioPorto, SVP of Global Marketing & Commercialization, +1 617 694 2918, jmz@bioporto.com
Hanne Foss, BioPorto, Head of Investor Relations, +45 4529 0000, investor@bioporto.com

About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units.

About BioPorto
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.